## Edgar Filing: INTERPHARM HOLDINGS INC - Form NT 10-K

# INTERPHARM HOLDINGS INC

Form NT 10-K September 28, 2007

# U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### FORM 12b-25

#### NOTIFICATION OF LATE FILING

x Form 10-K and Form 10-KSB o Form 20-F o Form 11-K o Form 10-Q and Form 10-QSB o Form N-SAR

For Period Ended: June 30, 2007

- o Transition Report on Form 10-K
- o Transition Report on Form 20-F
- o Transition Report on Form 11-K
- o Transition Report on Form 10-Q
- o Transition Report on Form N-SAR

For the Transition Period Ended:

Read Attached Instruction Sheet Before Preparing form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

#### Part I - Registrant Information

Full Name of Registrant: Interpharm Holdings, Inc.

Former Name if Applicable:

Address of Principal Executive Office:

75 Adams Avenue

Hauppauge, New York 11788

(City, State and Zip Code)

### **Part II – Rules 12b-25(b) and (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

x (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

# Edgar Filing: INTERPHARM HOLDINGS INC - Form NT 10-K

- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

#### Part III - Narrative

State below in reasonable detail the reasons why Form 10-K and Form 10-KSB, 20-F, 11-K, 10-Q and Form 10-QSB, N-SAR, or the transition report or portion thereof could not be filed within the prescribed period.

(Attach Extra Sheets if Needed)

Interpharm Holdings, Inc. (the "Company") requires additional time to file its Annual Report on Form 10-K in order to ensure the accuracy of the information reported due to the recent implementation of new financial and operational software, systems and controls.

#### Part IV – Other Information

1. Name and telephone number of person to contact in regard to this notification:

Peter Giallorenzo (631) 952-0214 (Name) (Area Code) (Telephone Number)

2. Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed. If the answer is no, Identify report(s).

x Yes o No

3. It is anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

o Yes xNo

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

# Edgar Filing: INTERPHARM HOLDINGS INC - Form NT 10-K

Interpharm Holdings, Inc.	
(Name of Registrant as specified in charter)	

(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

By: /s/ Peter Giallorenzo Date: September 28, 2007 Peter Giallorenzo

> Chief Financial Officer and **Chief Operating Officer**

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.